Product Information

CAS No.	1802148-05-5
Product Name	Brensocatib

Biological Targets

CTSC

Associated Conditions

cystic fibrosis·kidney disease·Bronchiectasis·COVID-19·liver disease

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial.

The Lancet. Respiratory medicine • Vol. 10, Issue 12 • 2022

PMID: 36075243 PMC: PMC9442496 DOI: 10.1016/S2213-2600(22)00261-2

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020

PMID: 32020584 PMC: PMC7160657 DOI: 10.1111/imm.13175

Dipeptidyl Peptidase 1 Inhibitor AZD7986 Induces a Sustained, Exposure-Dependent Reduction in Neutrophil Elastase Activity in Healthy Subjects.

Clinical pharmacology and therapeutics • Vol. 104, Issue 6 • 2018

PMID: 29484635 PMC: PMC6282495 DOI: 10.1002/cpt.1053

Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).

Journal of medicinal chemistry • Vol. 59, Issue 20 • 2016

PMID: 27690432 DOI: 10.1021/acs.jmedchem.6b01127

Brensocatib

CAS No.	1802148-05-5
MDL No.	N/A
MF	C₂₃H₂₄N₄O₄
MW	420.50
InChI Key	AEXFXNFMSAAELR-RXVVDRJESA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1802148-05-5
Product Name	Brensocatib

Biological Targets

CTSC

Associated Conditions

cystic fibrosis·kidney disease·Bronchiectasis·COVID-19·liver disease

* The information provided here is compiled from public sources and is for reference only.

Brensocatib

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Brensocatib

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Documentation

Brensocatib

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Related Articles

Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial.

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Dipeptidyl Peptidase 1 Inhibitor AZD7986 Induces a Sustained, Exposure-Dependent Reduction in Neutrophil Elastase Activity in Healthy Subjects.

Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).

Similar Products

DPP1-IN-1 (hydrate)

Brensocatib

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Related Articles

Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial.

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Dipeptidyl Peptidase 1 Inhibitor AZD7986 Induces a Sustained, Exposure-Dependent Reduction in Neutrophil Elastase Activity in Healthy Subjects.

Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).

Similar Products

DPP1-IN-1 (hydrate)

Documentation